Extended P2Y12 inhibitor monotherapy found to benefit high-risk acute coronary syndrome patients
Extended P2Y12 inhibitor monotherapy beyond 12 months after percutaneous coronary intervention (PCI) reduces bleeding and ischemic events in acute coronary syndrome (ACS) patients at high risk for both types of events. That's ...
Aug 28, 2023
0
28